A Phase II Study Testing the Activity and Safety of AGS-004 as an Immunotherapeutic in Successfully ART-Treated Subjects Infected With HIV-1 in Combination With ART Followed by ART Interruption.

Trial Profile

A Phase II Study Testing the Activity and Safety of AGS-004 as an Immunotherapeutic in Successfully ART-Treated Subjects Infected With HIV-1 in Combination With ART Followed by ART Interruption.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jul 2014

At a glance

  • Drugs AGS 004 (Primary)
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Sponsors Argos Therapeutics Inc
  • Most Recent Events

    • 04 Mar 2014 New findings from this trial will be presented at the Conference on Retroviruses and Opportunistic Infections (CROI), according to Argos Therapeutics media release.
    • 16 Sep 2013 Follow-up analysis will be published in October in JAIDS: Journal of Acquired Immune Deficiency Syndromes, according to an Argos Therapeutics media release.
    • 09 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top